Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin in Parkinson's Disease Psychosis (ACP-103-020)
NCT01174004Phase 3Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Jul 2010
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Pimavanserin with Placebo (2 arms). Primary endpoint: Scale for Assessment of Positive Symptoms - Parkinson's Disease at Day 43. Started Jul 2010; status: completed.
02
Drugs
pimavanserin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01174004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01174004.